NO314452B1 - Hydroksam- og karboksylsyre-derivater med MMP- og TNF- inhiberingsaktivitet,anvendelse derav og farmasöytiske preparater inneholdende dissederivater - Google Patents

Hydroksam- og karboksylsyre-derivater med MMP- og TNF- inhiberingsaktivitet,anvendelse derav og farmasöytiske preparater inneholdende dissederivater Download PDF

Info

Publication number
NO314452B1
NO314452B1 NO19990543A NO990543A NO314452B1 NO 314452 B1 NO314452 B1 NO 314452B1 NO 19990543 A NO19990543 A NO 19990543A NO 990543 A NO990543 A NO 990543A NO 314452 B1 NO314452 B1 NO 314452B1
Authority
NO
Norway
Prior art keywords
acid
hydroxyamide
alkyl
phenyl
phenylpentanoic
Prior art date
Application number
NO19990543A
Other languages
English (en)
Norwegian (no)
Other versions
NO990543L (no
NO990543D0 (no
Inventor
David Alan Owen
John Gary Montana
John Fraser Keily
Robert John Watson
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of NO990543D0 publication Critical patent/NO990543D0/no
Publication of NO990543L publication Critical patent/NO990543L/no
Publication of NO314452B1 publication Critical patent/NO314452B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
NO19990543A 1996-08-07 1999-02-05 Hydroksam- og karboksylsyre-derivater med MMP- og TNF- inhiberingsaktivitet,anvendelse derav og farmasöytiske preparater inneholdende dissederivater NO314452B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity
PCT/GB1997/002129 WO1998005635A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (3)

Publication Number Publication Date
NO990543D0 NO990543D0 (no) 1999-02-05
NO990543L NO990543L (no) 1999-04-06
NO314452B1 true NO314452B1 (no) 2003-03-24

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990543A NO314452B1 (no) 1996-08-07 1999-02-05 Hydroksam- og karboksylsyre-derivater med MMP- og TNF- inhiberingsaktivitet,anvendelse derav og farmasöytiske preparater inneholdende dissederivater

Country Status (17)

Country Link
US (1) US6118001A (da)
EP (1) EP0968182B1 (da)
JP (1) JP2000517297A (da)
KR (1) KR20000029858A (da)
CN (1) CN1227540A (da)
AT (1) ATE266000T1 (da)
AU (1) AU730464B2 (da)
BR (1) BR9711027A (da)
CA (1) CA2263154A1 (da)
CZ (1) CZ297278B6 (da)
DE (1) DE69729007T2 (da)
DK (1) DK0968182T3 (da)
ES (1) ES2217425T3 (da)
NO (1) NO314452B1 (da)
PL (1) PL193829B1 (da)
PT (1) PT968182E (da)
WO (1) WO1998005635A1 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5337498A (en) 1997-01-22 1998-08-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
IL131494A (en) * 1997-03-04 2005-06-19 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AU763113B2 (en) 1997-11-21 2003-07-10 Pharmacia & Upjohn Company Alpha-hydroxy, -amino, and halo derivatives of beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
EP0965592A1 (en) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Process for preparing 3-arylsulfur hydroxamic acids
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1107953A1 (en) 1998-08-29 2001-06-20 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
GB9911073D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9911075D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
AU3385401A (en) * 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2001087883A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
EP1292576A1 (en) 2000-05-15 2003-03-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AU778368B2 (en) 2000-05-15 2004-12-02 Darwin Discovery Limited Hydroxamic acid derivatives
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003099789A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc. Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
DE10226370B4 (de) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrat für ein elektronisches Bauteil, Verwendung des Substrates, Verfahren zur Erhöhung der Ladungsträgermobilität und Organischer Feld-Effekt Transistor (OFET)
DE10233085B4 (de) 2002-07-19 2014-02-20 Dendron Gmbh Stent mit Führungsdraht
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
JP2008538776A (ja) * 2005-04-25 2008-11-06 ノバルティス アクチエンゲゼルシャフト ペプチド脱ホルミル酵素(pdf)阻害剤として有用なイミダゾ[1,2−a]ピリジン誘導体
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0604142D0 (en) 2006-03-01 2006-04-12 Sterix Ltd Compound
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
JP2010504281A (ja) * 2006-07-27 2010-02-12 エミスフェアー・テクノロジーズ・インク アリールスルファニル化合物、および活性薬剤を送達するための組成物
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
EP2254485B1 (en) 2008-02-22 2017-08-30 Covidien LP Apparatus for flow restoration
PL3192874T3 (pl) 2008-06-18 2020-06-29 Oxford Biomedica (Uk) Limited Oczyszczanie wirusa
DK2364362T3 (da) 2008-11-12 2016-01-25 Ospedale San Raffaele Srl Genvektor til induktion af transgenspecifik immuntolerance
SG175839A1 (en) 2009-04-30 2011-12-29 San Raffaele Centro Fond Gene vector
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
US20160024125A1 (en) 2013-03-11 2016-01-28 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
EP3613859A1 (en) 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
GB201418965D0 (da) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201608944D0 (en) 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
DE102017211110A1 (de) * 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh Verfahren zur Herstellung eines Silans, Verfahren zur Modifizierung einer Kieselsäure mit dem Silan und modifizierte Kieselsäure
GB201807944D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
CA3104948A1 (en) 2018-06-25 2020-01-02 Ospedale San Raffaele S.R.L Gene therapy
SG11202103647YA (en) 2018-10-11 2021-05-28 Ospedale San Raffaele Srl Selection by means of artificial transactivators
JP2022517342A (ja) 2019-01-18 2022-03-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
JP2023516493A (ja) 2020-03-13 2023-04-19 オックスフォード バイオメディカ(ユーケー)リミテッド レンチウイルスベクター
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2022064061A1 (en) 2020-09-28 2022-03-31 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
CA3188667A1 (en) 2020-09-28 2022-03-31 Nicola Vannini Compositions and methods for increasing stem cell function
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
JP2024506751A (ja) 2021-02-01 2024-02-14 イプシレン バイオ エス.アール.エル. 遺伝子サイレンシング
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
WO2022233767A1 (en) 2021-05-05 2022-11-10 Société des Produits Nestlé S.A. Urolithin for increasing stem cell function
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127722A (en) * 1975-10-02 1978-11-28 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
DE2804576A1 (de) * 1977-02-15 1978-08-17 Lafon Labor Phenylamidin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
CA2219973A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds and their therapeutic use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
DK0871439T3 (da) * 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
ID21897A (id) * 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Also Published As

Publication number Publication date
AU3856497A (en) 1998-02-25
CN1227540A (zh) 1999-09-01
WO1998005635A1 (en) 1998-02-12
JP2000517297A (ja) 2000-12-26
KR20000029858A (ko) 2000-05-25
DE69729007T2 (de) 2005-04-07
DK0968182T3 (da) 2004-08-16
EP0968182A1 (en) 2000-01-05
AU730464B2 (en) 2001-03-08
US6118001A (en) 2000-09-12
CZ297278B6 (cs) 2006-10-11
CZ36899A3 (cs) 1999-07-14
CA2263154A1 (en) 1998-02-12
DE69729007D1 (de) 2004-06-09
PL331598A1 (en) 1999-08-02
EP0968182B1 (en) 2004-05-06
NO990543L (no) 1999-04-06
NO990543D0 (no) 1999-02-05
PL193829B1 (pl) 2007-03-30
ES2217425T3 (es) 2004-11-01
ATE266000T1 (de) 2004-05-15
PT968182E (pt) 2004-08-31
BR9711027A (pt) 1999-08-17

Similar Documents

Publication Publication Date Title
NO314452B1 (no) Hydroksam- og karboksylsyre-derivater med MMP- og TNF- inhiberingsaktivitet,anvendelse derav og farmasöytiske preparater inneholdende dissederivater
US5120718A (en) Candida acid protease inhibiting compounds
US5554767A (en) Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
EP0960108B1 (en) Matrix metalloproteinase inhibitors
RU2210567C2 (ru) Производные гидроксамовой и карбоновой кислоты, имеющие mmp ингибирующую активность, и фармацевтическая композиция на их основе
US6329418B1 (en) Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1381602A1 (en) Heterocyclyldicarbamides as caspase inhibitors
EA002810B1 (ru) Сульфамидные ингибиторы металлопротеаз
US6566384B1 (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
JPH08508034A (ja) フェノキシフェニル酢酸誘導体
HU217344B1 (hu) Merkapto-acil-dipeptid-származékok és alkalmazásuk metalloproteináz inhibitor hatású gyógyszerkészítmények előállítására
JP2003525203A (ja) ヒドロキサムおよびカルボン酸誘導体
DE69620639T2 (de) Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
NO326266B1 (no) Hydroksam- og karboksylsyrederivater, farmasoytiske preparater inneholdende slike for anvendelse i terapi samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling eller forebygging av sykdommer
US6455531B1 (en) Hydroxamic acid derivatives
WO1997012861A1 (en) Mercaptoamide derivatives and their therapeutic use
EP1053233B1 (en) Hydroxamic and carboxylic acid derivatives
US6680338B2 (en) Hydroxamic and carboxylic acid derivatives
MXPA99001298A (es) Derivados de acido hidroxamico y carboxilico que tienen actividad inhibitoria de mpm y fnt
JP2001522843A (ja) Mmpおよびtnf抑制作用を有するヒドロキサム酸およびカルボン酸誘導体
US7015234B2 (en) Hydroxamic acid derivatives
MXPA00007570A (en) Hydroxamic and carboxylic acid derivatives
MXPA00004747A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
CZ267699A3 (cs) Deriváty arylsulfonylaminohydroxamové kyseliny, farmaceutický prostředek, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení